Search

Your search keyword '"Oliveira-Mendes, Barbara"' showing total 20 results
Start Over Author "Oliveira-Mendes, Barbara"
20 results on '"Oliveira-Mendes, Barbara"'

4. Determination of hyaluronidase activity in Tityus spp. Scorpion venoms and its inhibition by Brazilian antivenoms

Author

Guerra-Duarte, Clara, Rebello Horta, Carolina Campolina, Ribeiro Oliveira-Mendes, Bárbara Bruna, de Freitas Magalhães, Bárbara, Costal-Oliveira, Fernanda, Stransky, Stephanie, Fonseca de Freitas, Cláudio, Campolina, Délio, Pereira de Oliveira Pardal, Pedro, Lira-da-Silva, Rejane, Machado de Ávila, Ricardo Andrés, Kalapothakis, Evanguedes, and Chávez-Olórtegui, Carlos

Published
2019
Full Text
View/download PDF

6. Structure-function relationship of new peptides activating human Nav1.1

Author

Lopez, Ludivine, primary, De Waard, Stephan, additional, Meudal, Hervé, additional, Caumes, Cécile, additional, Khakh, Kuldip, additional, Peigneur, Steve, additional, Oliveira-Mendes, Barbara, additional, Lin, Sophia, additional, De Waele, Jolien, additional, Montnach, Jérôme, additional, Cestèle, Sandrine, additional, Tessier, Agnès, additional, Johnson, J.P., additional, Mantegazza, Massimo, additional, Tytgat, Jan, additional, Cohen, Charles, additional, Béroud, Rémy, additional, Bosmans, Frank, additional, Landon, Céline, additional, and De Waard, Michel, additional

Published
2023
Full Text
View/download PDF

7. The Venom from Lasiodora sp.: A Mygalomorph Brazilian Spider

Author

Horta, Carolina Campolina Rebello, Chatzaki, Maria, Oliveira-Mendes, Bárbara Bruna Ribeiro, do Carmo, Anderson Oliveira, de Faria Siqueira, Flávia, Kalapothakis, Evanguedes, Gopalakrishnakone, P., Editor-in-chief, Corzo, Gerardo A., editor, de Lima, Maria Elena, editor, and Diego-García, Elia, editor

Published
2016
Full Text
View/download PDF

9. SARS-CoV-2 E and 3a Proteins Are Inducers of Pannexin Currents

Author

Oliveira-Mendes, Barbara B. R., primary, Alameh, Malak, additional, Ollivier, Béatrice, additional, Montnach, Jérôme, additional, Bidère, Nicolas, additional, Souazé, Frédérique, additional, Escriou, Nicolas, additional, Charpentier, Flavien, additional, Baró, Isabelle, additional, De Waard, Michel, additional, and Loussouarn, Gildas, additional

Published
2023
Full Text
View/download PDF

10. Predicting hERG repolarization power at 37°C from recordings at room temperature

Author

Oliveira‐Mendes, Barbara B. R., primary, Alameh, Malak, additional, Montnach, Jérôme, additional, Ollivier, Béatrice, additional, Gibaud, Solène, additional, Feliciangeli, Sylvain, additional, Lesage, Florian, additional, Charpentier, Flavien, additional, Loussouarn, Gildas, additional, De Waard, Michel, additional, and Baró, Isabelle, additional

Published
2023
Full Text
View/download PDF

13. Escritos sobre políticas públicas, infância e juventude

Author

de Oliveira Martins Siqueira, Kassia, primary, Expedito Silva Darós, Lindomar, additional, Cavalcante Roque da Silva, Davi, additional, da Silva Alcantara, Luciana, additional, Freire Caldeira, Zelia, additional, Piedade da Silva Santos, Érika, additional, Ponte Brandão, Eduardo, additional, Fontes Baptista, Rachel, additional, Maria Gomes Ribeiro Fernandes, Ângela, additional, Ferreira Silva de Alcantara, Elisa, additional, Baptista Campanuci Queiroz, Felipe, additional, Santa Oliveira Maria Ayres, Lygia, additional, Oliveira Mendes, Barbara, additional, Terra de Almeida, Ramon, additional, and Helena Darós, Maria, additional

Published
2018
Full Text
View/download PDF

15. Chemical Synthesis of a Functional Fluorescent-Tagged α-Bungarotoxin

Author

Brun, Oliver, primary, Zoukimian, Claude, additional, Oliveira-Mendes, Barbara, additional, Montnach, Jérôme, additional, Lauzier, Benjamin, additional, Ronjat, Michel, additional, Béroud, Rémy, additional, Lesage, Frédéric, additional, Boturyn, Didier, additional, and De Waard, Michel, additional

Published
2022
Full Text
View/download PDF

16. Synthetic Analogues of Huwentoxin-IV Spider Peptide With Altered Human NaV1.7/NaV1.6 Selectivity Ratios

Author

Lopez, Ludivine, primary, Montnach, Jérôme, additional, Oliveira-Mendes, Barbara, additional, Khakh, Kuldip, additional, Thomas, Baptiste, additional, Lin, Sophia, additional, Caumes, Cécile, additional, Wesolowski, Steven, additional, Nicolas, Sébastien, additional, Servent, Denis, additional, Cohen, Charles, additional, Béroud, Rémy, additional, Benoit, Evelyne, additional, and De Waard, Michel, additional

Published
2021
Full Text
View/download PDF

17. A standardised hERG phenotyping pipeline to evaluate KCNH2 genetic variant pathogenicity

Author

Oliveira‐Mendes, Barbara, primary, Feliciangeli, Sylvain, additional, Ménard, Mélissa, additional, Chatelain, Frank, additional, Alameh, Malak, additional, Montnach, Jérôme, additional, Nicolas, Sébastien, additional, Ollivier, Béatrice, additional, Barc, Julien, additional, Baró, Isabelle, additional, Schott, Jean‐Jacques, additional, Probst, Vincent, additional, Kyndt, Florence, additional, Denjoy, Isabelle, additional, Lesage, Florian, additional, Loussouarn, Gildas, additional, and De Waard, Michel, additional

Published
2021
Full Text
View/download PDF

19. Toxins from Venomous Arthropods in Brazil: Patents and Potential Biotechnological Applications

Author

de Castro, Pedro Henrique Cardoso, Paiva, Ana Luiza Bittencourt, Oliveira-Mendes, Barbara Bruna Ribeiro, Guerra-Duarte, Clara, and Matavel, Alessandra

Abstract

Background: The diversity of components in arthropod venoms constitute a rich source of bioactive molecules. Brazil is the most biodiverse country in the world, comprising 15 to 20% of the total catalogued species, with approximately 103,870 animal species including arthropods. Although many articles mention the biotechnological potential of these venoms and toxins, only a few studies compile the patented uses of these molecules. Objective: This review describes the knowledge about the molecular mechanism of venoms and toxins with biotechnological potential, and lists the patents deposited up to 2021 related to the main medical relevant arthropods in Brazil including the orders Araneae (spider genus Phoneutria, Loxosceles, Latrodectus), Scorpiones (scorpion genus Tityus), Lepidoptera (caterpillar genus Lonomia), and Hymenoptera. Methods: The international patent search engine “Espacenet” and the “Brazilian patent office” were used to search the patents described in this article. Results: Up to date, 34 patents have been filled involving these Brazilian arthropods' venoms or toxins. Most of them (20) claimed biotechnological inventions with spider toxins, mainly from the genus Phoneutria. Only seven inventions involved venom or toxins from scorpions, one from a bee, three from wasps, and three from caterpillars. Conclusions: Brazil is one of the main references in venoms and toxins studies; however, the limited number of deposited patents related to this area by Brazilian researchers do not reflect their pioneer position in this field. On the other hand, patents were well described and made with purified toxins, rather than with the whole venom. Nevertheless, the vast publication record of venom and toxin characterization that leads to a better understanding of their molecular mechanisms paves the way for turning these promising molecules into possible products.

Published
2022
Full Text
View/download PDF

20. Synthetic Analogues of Huwentoxin-IV Spider Peptide With Altered Human Na V 1.7/Na V 1.6 Selectivity Ratios.

Author

Lopez L, Montnach J, Oliveira-Mendes B, Khakh K, Thomas B, Lin S, Caumes C, Wesolowski S, Nicolas S, Servent D, Cohen C, Béroud R, Benoit E, and De Waard M

Abstract

Huwentoxin-IV (HwTx-IV), a peptide discovered in the venom of the Chinese bird spider Cyriopagopus schmidti , has been reported to be a potent antinociceptive compound due to its action on the genetically-validated Na V 1.7 pain target. Using this peptide for antinociceptive applications in vivo suffers from one major drawback, namely its negative impact on the neuromuscular system. Although studied only recently, this effect appears to be due to an interaction between the peptide and the Na V 1.6 channel subtype located at the presynaptic level. The aim of this work was to investigate how HwTx-IV could be modified in order to alter the original human (h) Na V 1.7/Na V 1.6 selectivity ratio of 23. Nineteen HwTx-IV analogues were chemically synthesized and tested for their blocking effects on the Na + currents flowing through these two channel subtypes stably expressed in cell lines. Dose-response curves for these analogues were generated, thanks to the use of an automated patch-clamp system. Several key amino acid positions were targeted owing to the information provided by earlier structure-activity relationship (SAR) studies. Among the analogues tested, the potency of HwTx-IV E 4 K was significantly improved for hNa V 1.6, leading to a decreased hNa V 1.7/hNa V 1.6 selectivity ratio (close to 1). Similar decreased selectivity ratios, but with increased potency for both subtypes, were observed for HwTx-IV analogues that combine a substitution at position 4 with a modification of amino acid 1 or 26 (HwTx-IV E 1 G/E 4 G and HwTx-IV E 4 K/R 26 Q). In contrast, increased selectivity ratios (>46) were obtained if the E 4 K mutation was combined to an additional double substitution ( R 26 A/Y 33 W) or simply by further substituting the C-terminal amidation of the peptide by a carboxylated motif, linked to a marked loss of potency on hNa V 1.6 in this latter case. These results demonstrate that it is possible to significantly modulate the selectivity ratio for these two channel subtypes in order to improve the potency of a given analogue for hNa V 1.6 and/or hNa V 1.7 subtypes. In addition, selective analogues for hNa V 1.7, possessing better safety profiles, were produced to limit neuromuscular impairments., Competing Interests: Authors KK, SL, SW, and CC were employed by company Xenon Pharmaceuticals. Authors BT, CC, RB, and LL were employed by company Smartox Biotechnology. MDW is a consultant and founder of Smartox Biotechnology. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2021 Lopez, Montnach, Oliveira-Mendes, Khakh, Thomas, Lin, Caumes, Wesolowski, Nicolas, Servent, Cohen, Béroud, Benoit and De Waard.)

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results